Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease

被引:12
作者
Mhanni, A. A. [1 ,2 ]
Kozenko, M. [3 ]
Hartley, J. N. [2 ]
Deneau, M. [4 ]
El-Matary, W. [1 ]
Rockman-Greenberg, C. [1 ,2 ]
机构
[1] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada
[2] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3T 2N2, Canada
[3] McMaster Univ, Dept Pediat, Hamilton, ON L8S 4L8, Canada
[4] Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA
关键词
ENZYME REPLACEMENT THERAPY; MEDIASTINAL LYMPHADENOPATHY; MESENTERIC MASS;
D O I
10.1016/j.ymgmr.2015.12.001
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gaucher disease (OMIM#230800) is caused by beta-glucosidase deficiency and primarily involves the mononuclear phagocyte system (also called Reticuloendothelial System or Macrophage System). The disease is classified into three main phenotypes based on the presence or absence of neurological manifestations: non-neuronopathic (type 1), acute neuronopathic (type 2) and chronic neuronopathic (type 3). Typical manifestations include hepatosplenomegaly, skeletal deformities, hematological abnormalities, interstitial lung fibrosis and neurodegeneration in neuronopathic cases. Mesenteric lymphadenopathy with resultant protein losing enteropathy (PLE) has only been rarely described. Mesenteric lymphadenopathy may lead to intestinal lymphatic obstruction and secondary lymphangiectasia resulting in chronic diarrhea, abdominal pain and weight loss. Fecal protein loss with secondary hypoalbuminemia can be significant. We report a male with Chronic Neuronopathic Gaucher disease (GD) (homozygous for c.1448T>C (NM_000157.3) GBA mutation) who at 16 years of age developed intractable abdominal pain, diarrhea and weight loss. This was caused by PLE secondary to intestinal lymphangiectasia caused by calcified mesenteric lymphadenopathy despite prior long term enzyme replacement therapy (ERT) and/or substrate reduction therapy (SRT). His older similarly affected sister who had been receiving treatment with ERT and/or SRT remains stable on these treatments with no evidence of mesenteric lymphadenopathy. Medical management with total parenteral nutrition, daily medium chain triglyceride-oil (MCT) supplementation, low dose oral budesonide, continued oral SRT and an increased dose of parenteral ERT has stabilized his condition with resolution of the gastrointestinal symptoms and appropriate weight gain. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:13 / 15
页数:3
相关论文
共 11 条
[1]   Mesenteric and Mediastinal Lymphadenopathy in Egyptian Children With Gaucher Disease Types 1 and 3 Treated With Enzyme Replacement Therapy [J].
Abdelwahab, Magy ;
SeifEldien, Hadeel M. .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (05) :e316-e322
[2]   Gaucher disease: Progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy [J].
Burrow, T. Andrew ;
Cohen, Mitchell B. ;
Bokulic, Ronald ;
Deutsch, Gail ;
Choudhary, Arabinda ;
Falcone, Richard A., Jr. ;
Grabowski, Gregory A. .
JOURNAL OF PEDIATRICS, 2007, 150 (02) :202-206
[3]   CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: Clinical, histopathologic, and biochemical findings [J].
Burrow, Thomas A. ;
Sun, Ying ;
Prada, Carlos E. ;
Bailey, Laurie ;
Zhang, Wujuan ;
Brewer, Amanda ;
Wu, Steve W. ;
Setchell, Kenneth D. R. ;
Witte, David ;
Cohen, Mitchell B. ;
Grabowski, Gregory A. .
MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) :233-241
[4]   Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination [J].
Capablo, Jose L. ;
Franco, Rafael ;
de Cabezon, Alicia Saenz ;
Alfonso, Pilar ;
Pocovi, Miguel ;
Giraldo, Pilar .
EPILEPSIA, 2007, 48 (07) :1406-1408
[5]   Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III [J].
Cox-Brinkman, J. ;
van Breemen, M. J. ;
van Maldegem, B. T. ;
Bour, L. ;
Donker, W. E. ;
Hollak, C. E. M. ;
Wijburg, F. A. ;
Aerts, J. M. F. G. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 (06) :745-752
[6]   Ultrastructural features of Gaucher disease treated with enzyme replacement therapy presenting as mesenteric mass lesions [J].
Fowler, D. J. ;
Weber, M. A. ;
Anderson, G. ;
Malone, M. ;
Sebire, N. J. ;
Vellodi, A. .
FETAL AND PEDIATRIC PATHOLOGY, 2006, 25 (05) :241-248
[7]   Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease [J].
Lee, Beom Hee ;
Kim, Dae-Yeon ;
Kim, Gu-Hwan ;
Cho, Kyung-Ja ;
Yoon, Hye-Kyung ;
Yoo, Han-Wook .
MOLECULAR GENETICS AND METABOLISM, 2012, 105 (03) :522-524
[8]   Mesenteric mass in a young girl - an unusual site for Gaucher's disease [J].
Lim, AKP ;
Vellodi, A ;
McHugh, K .
PEDIATRIC RADIOLOGY, 2002, 32 (09) :674-676
[9]   Goal-oriented therapy with miglustat in Gaucher disease [J].
Pastores, Gregory M. ;
Giraldo, Pilar ;
Cherin, Patrick ;
Mehta, Atul .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) :23-37
[10]   Randomized, Controlled Trial of Miglustat in Gaucher's Disease Type 3 [J].
Schiffmann, Raphael ;
Fitzgibbon, Edmond J. ;
Harris, Chris ;
DeVile, Catherine ;
Davies, Elin H. ;
Abel, Larry ;
van Schaik, Ivo N. ;
Benko, William ;
Timmons, Margaret ;
Ries, Markus ;
Vellodi, Ashok .
ANNALS OF NEUROLOGY, 2008, 64 (05) :514-522